

US Intravenous Immunoglobulin Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Type (IgG, IgM, IgA, and Others), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and End User (Hospitals, Specialty Clinics, and Others)

<https://marketpublishers.com/r/U30ACAB63EA1EN.html>

Date: April 2023

Pages: 145

Price: US\$ 3,000.00 (Single User License)

ID: U30ACAB63EA1EN

Abstracts

The US intravenous immunoglobulin market size was valued at US\$ 4,439.26 million in 2022 and is projected to reach US\$ 7,105.63 million by 2028; it is estimated to grow at a CAGR 8.2% during 2023–2028. The increasing geriatric population favors the growth of the US intravenous immunoglobulin market.

Immunoglobulins are the antibodies produced naturally by the body's immune system, which help fight infection and disease. Individuals with immunoglobulin deficiency require the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIGs are extracted from human plasma.

These antibodies are used in the treatment of various immunological, hematological, and neurological illnesses. Factors such as rising immunodeficiency disease prevalence and increasing geriatric population in the US drive the US intravenous immunoglobulin market growth. However, adverse effects of immunoglobulin therapy hamper the market growth.

IVIGs are used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. The IVIG is a standard therapy to treat most primary immunodeficiencies (PIDs). According to data by John Hopkins Medicine, ~3% of the total US population, i.e., 10 million people, suffers from autoimmune diseases. As per the National Institute of Allergy and Infectious Diseases (NIAID), there are over 200 different types of primary immune deficiency diseases (PIDDs) affecting ~500,000 people in the US. The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. The Rare Diseases Organization states that the incidence rate of ITP in adults is ~3.3 per 100,000 per year in the US. Per the National Multiple Sclerosis Society study report, published in 2019, ~1 million adults (~913,925) were affected by multiple sclerosis (MS) in the US. According to the MS Discovery Forum, ~200 new cases are diagnosed each week in the US. Thus, the increasing prevalence of immunodeficiency diseases drives the growth of the US intravenous immunoglobulin market.

Many market players and research institutes operating in the US intravenous immunoglobulin market are developing advanced technologies to expand their product portfolios and increase their market shares. Rising immunodeficiency disease prevalence, product approvals, and collaborations are among the factors driving the US intravenous immunoglobulin market size.

A few of the recent developments related to US intravenous immunoglobulin are mentioned below:

In April 2020, Kamada Ltd. and Kedrion Biopharma collaborated to develop, manufacture, and distribute a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment against COVID-19. The announcement follows separate previous reports by the two entities concerning initiating development programs for such products.

In January 2022, LFB and Kedrion joined forces in an industrial cooperation agreement

to increase the availability of immunoglobulins for patients in France. In the framework of this industrial partnership, Kedrion manufactured immunoglobulins in Hungary from LFB plasma which was collected in France by the “Etablissement Français du Sang” (EFS). LFB imported these immunoglobulins manufactured by Kedrion in France and complemented its immunoglobulins, which are available in hospitals across France, in agreement with and under the control of French health authorities.

In April 2020, In April 2020, Octapharma collaborated with CSL, Takeda, BPL, Biotest, and LFB to investigate the possibility of treating COVID-19 with plasma-derived hyperimmune immunoglobulins.

US Intravenous Immunoglobulin Market, By Type-Based Insights

Based on product type, the US intravenous immunoglobulin market is segmented into IgG, IgM, IgA, and others. In 2022, the IgG segment held the largest share of the market. Moreover, the same segment is expected to record the highest CAGR during the forecast period.

IVIg is a replacement therapy and treatment for patients with antibody deficiencies or for those who suffer from immunodeficiency disorders. For instance, in primary or secondary hypogammaglobulinemia, IVIg replacement therapy provides protection against infections by administering an adequate volume of IgG in the blood. IVIg is a blood product prepared from serum derived from 1,000–15,000 donors per batch where only IgG is purified from plasma to produce IVIg products. Therefore, IVIg used for treatment therapies contains 95–98% pure IgG with small amounts of other plasma proteins, including IgA and IgM.

Thus, wide applications of IgG in treating several categories of disorders are among the factors contributing to the growth of the US intravenous immunoglobulin market.

US Intravenous Immunoglobulin Market, By End User-Based Insights

The US intravenous immunoglobulin market, based on end user, is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. In 2022, the immunodeficiency diseases segment held the largest market share in . The same segment is expected to grow at the fastest rate during the coming years.

The World Health Organization (WHO), the US Census Bureau, and the US National Library of Medicine are a few of the major primary and secondary sources referred to while preparing the report on the US intravenous immunoglobulin market.

Contents

1. INTRODUCTION

- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
 - 1.3.1 Intravenous Immunoglobulin Market – By Type
 - 1.3.2 Intravenous Immunoglobulin Market – By Application
 - 1.3.3 Intravenous Immunoglobulin Market – By Distribution Channel
 - 1.3.4 Intravenous Immunoglobulin Market – By End User
 - 1.3.5 Intravenous Immunoglobulin Market – By Country

2. INTRAVENOUS IMMUNOGLOBULIN MARKET – KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

4. INTRAVENOUS IMMUNOGLOBULIN MARKET – MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis
 - 4.2.1 US – PEST Analysis
- 4.3 Expert Opinion
- 4.4 Pipeline Product

5. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET – KEY MARKET DYNAMICS

- 5.1 Market Drivers
 - 5.1.1 Rising Immunodeficiency Disease Prevalence
 - 5.1.2 Increasing Geriatric Population
- 5.2 Market Restraints
 - 5.2.1 Adverse Effects of Immunoglobulin Therapy
- 5.3 Market Opportunities

- 5.3.1 Flourishing Pharmaceutical Industry
- 5.4 Future Trends
 - 5.4.1 Strong Pipeline of IVIG Candidates
- 5.5 Impact Analysis

6. INTRAVENOUS IMMUNOGLOBULIN MARKET – US ANALYSIS

- 6.1 United States Intravenous Immunoglobulin Market Revenue Forecast and Analysis
- 6.2 Market Positioning of Key Players

7. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS – BY TYPE

- 7.1 Overview
- 7.2 United States Intravenous Immunoglobulin Market, by Type – Volume and Forecast to 2028 (Metric Tons)
- 7.3 United States Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US\$ Million)
- 7.4 IgG
 - 7.4.1 Overview
 - 7.4.2 IgG: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)
- 7.5 IgM
 - 7.5.1 Overview
 - 7.5.2 IgM: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)
- 7.6 IgA
 - 7.6.1 Overview
 - 7.6.2 IgA: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)
- 7.7 Others
 - 7.7.1 Overview
 - 7.7.2 Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

8. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS – BY APPLICATION

- 8.1 Overview

8.2 United States Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US\$ Million)

8.3 Hypogammaglobulinemia

8.3.1 Overview

8.3.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

8.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIPD)

8.4.1 Overview

8.4.2 CIPD: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

8.5 Immunodeficiency Diseases

8.5.1 Overview

8.5.2 Immunodeficiency Disease: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

8.6 Myasthenia Gravis

8.6.1 Overview

8.6.2 Myasthenia Gravis: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

8.7 Multifocal Motor Neuropathy

8.7.1 Overview

8.7.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

8.8 Idiopathic Thrombocytopenic Purpura

8.8.1 Overview

8.8.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

8.9 Inflammatory Myopathies

8.9.1 Overview

8.9.2 Inflammatory Myopathies: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)

8.10 Specific Antibody Deficiency

8.10.1 Overview

8.10.2 Specific Antibody Deficiency: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)

8.11 Guillain-Barre Syndrome

8.11.1 Overview

8.11.2 Guillain-Barre Syndrome: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

8.12 Others

8.12.1 Overview

8.12.2 Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

9. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS – BY DISTRIBUTION CHANNEL

9.1 Overview

9.2 United States Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

10. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS – BY END USER

10.1 Overview

10.2 United States Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

10.4 Specialty Clinics

10.4.1 Overview

10.4.2 Specialty Clinics: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

10.5 Others

10.5.1 Overview

10.5.2 Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

11. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET: IMPACT ASSESSMENT OF COVID-19 PANDEMIC

11.1 US: Impact Assessment of COVID-19 Pandemic

12. US INTRAVENOUS IMMUNOGLOBULIN MARKET – INDUSTRY LANDSCAPE

12.1 Overview

12.2 Growth Strategies in US Intravenous Immunoglobulin Market (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. COMPANY PROFILES

13.1 Takeda Pharmaceutical Co Ltd

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Grifols SA

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Pfizer Inc

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

- 13.3.6 Key Developments
- 13.4 ADMA Biologics, Inc.
 - 13.4.1 Key Facts
 - 13.4.2 Business Description
 - 13.4.3 Products and Services
 - 13.4.4 Financial Overview
 - 13.4.5 SWOT Analysis
 - 13.4.6 Key Developments
- 13.5 Bio Products Laboratory Ltd.
 - 13.5.1.1.1 Key Facts
 - 13.5.2 Business Description
 - 13.5.3 Products and Services
 - 13.5.4 Financial Overview
 - 13.5.5 SWOT Analysis
 - 13.5.6 Key Developments
- 13.6 Octapharma AG
 - 13.6.1 Key Facts
 - 13.6.2 Business Description
 - 13.6.3 Products and Services
 - 13.6.4 Financial Overview
 - 13.6.5 SWOT Analysis
 - 13.6.6 Key Developments
- 13.7 Kedrion SpA
 - 13.7.1 Key Facts
 - 13.7.2 Business Description
 - 13.7.3 Products and Services
 - 13.7.4 Financial Overview
 - 13.7.5 SWOT Analysis
 - 13.7.6 Key Developments
- 13.8 CSL Ltd
 - 13.8.1 Key Facts
 - 13.8.2 Business Description
 - 13.8.3 Products and Services
 - 13.8.4 Financial Overview
 - 13.8.5 SWOT Analysis
 - 13.8.6 Key Developments
- 13.9 LFB Group
 - 13.9.1 Key Facts
 - 13.9.2 Business Description

- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 Prothya Biosolutions B.V.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. APPENDIX

- 14.1 About The Insight Partners
- 14.2 Glossary of Terms

List Of Tables

LIST OF TABLES

Table 1. Pipeline Product Developments in the US Intravenous Immunoglobulin Market

Table 2. R&D Investments by Major Pharmaceuticals Companies in US

Table 3. United States Intravenous Immunoglobulin Market, by Type – Volume and Forecast to 2028 (Metric Tons)

Table 4. United States Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 5. United States Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US\$ Million)

Table 6. United States Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

Table 7. United States Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 8. Organic Developments in the US Intravenous Immunoglobulin Market

Table 9. Inorganic Developments in the US Intravenous Immunoglobulin Market

Table 10. Glossary of Terms

List Of Figures

LIST OF FIGURES

Figure 1. Intravenous Immunoglobulin Market Segmentation

Figure 2. United States Intravenous Immunoglobulin Market Overview

Figure 3. IgG Held Largest Share of Intravenous Immunoglobulin Market

Figure 4. United States Intravenous Immunoglobulin Market, Industry Landscape

Figure 5. US PEST Analysis

Figure 6. Expert Opinion

Figure 7. US Intravenous Immunoglobulin Market Impact Analysis of Drivers and Restraints

Figure 8. United States Intravenous Immunoglobulin Market – Revenue Forecast and Analysis – 2020- 2028

Figure 9. Market Positioning of Key Players in United States Intravenous Immunoglobulin Market

Figure 10. United States Intravenous Immunoglobulin Market, by Type, 2022 & 2028 (%)

Figure 11. IgG: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 12. IgM: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 13. IgA: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 14. Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 15. United States Intravenous Immunoglobulin Market, by Application, 2022 & 2028 (%)

Figure 16. Hypogammaglobulinemia: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

Figure 17. CIPD: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

Figure 18. Immunodeficiency Disease: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

Figure 19. Myasthenia Gravis: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

Figure 20. Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market– Revenue and Forecast to 2028 (US\$ Million)

Figure 21. Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market–

Revenue and Forecast to 2028 (US\$ Million)

Figure 22. Inflammatory Myopathies: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 23. Specific Antibody Deficiency: United States Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 24. Guillain-Barre Syndrome: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 25. Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 26. United States Intravenous Immunoglobulin Market, by Distribution Channel, 2022 & 2028 (%)

Figure 27. Hospital Pharmacy: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 28. Retail Pharmacy: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 29. Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 30. United States Intravenous Immunoglobulin Market, by End User, 2022 & 2028 (%)

Figure 31. Hospitals: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 32. Specialty Clinics: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 33. Others: United States Intravenous Immunoglobulins Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 34. Impact of COVID-19 Pandemic on US Intravenous Immunoglobulin Market

Figure 35. Growth Strategies in US Intravenous Immunoglobulin Market (%)

I would like to order

Product name: US Intravenous Immunoglobulin Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Type (IgG, IgM, IgA, and Others), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and End User (Hospitals, Specialty Clinics, and Others)

Product link: <https://marketpublishers.com/r/U30ACAB63EA1EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U30ACAB63EA1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970